Agios Pharmaceuticals AGIO Operating Lease Income - 2024 (Lessor)

Other financials

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Market cap$2.16B+18.1%

Enterprise value$2.08B+15.2%

P/S32.7×-16.7×

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Agios Pharmaceuticals's operating lease income - 2024 (lessor)?: Agios Pharmaceuticals (AGIO) reported operating lease income - 2024 (lessor) of $67K in Q1 2026.